Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06245629Recruiting
Comparing two drug combos for relapsed multiple myeloma
This trial looks at two different drug combinations given before a second stem cell transplant for multiple myeloma that has come back after first treatment. It aims to see if adding two extra drugs (bortezomib and bendamustine) to the standard drug (melphalan) works better than using the standard drug alone.
UppsalaAges 18 years+ - NCT06246162RecruitingPhase 1/Phase 2
Mitoxantrone liposome combo for high-risk multiple myeloma
This trial tests a liposomal form of mitoxantrone combined with other drugs for people with aggressive multiple myeloma (high-risk or spread outside the bone). The goal is to see if this approach helps control the cancer better.
Nantong, JiangsuAges 18–70 - NCT06247189Recruiting
ICOPE program for older adults with myeloma
This trial tests whether a program called ICOPE MONITOR, which uses a smartphone app or chatbot, can help older adults with multiple myeloma stay healthier and manage their care. It may be a good fit if you are 70+ and starting your first or second treatment.
ToulouseAges 70 years+ - NCT06248957Recruiting
Immune system study for people with hard-to-treat immune diseases
This study aims to understand the immune system in people who have immune problems or whose immune-related diseases are not helped by standard treatments. It may lead to better ways to diagnose and treat these conditions.
StockholmAges Any age - NCT06249373Recruiting
Low-intensity ultrasound to help new fistula mature
This study tests whether low-intensity ultrasound (LIPUS) can help a new arteriovenous fistula (AVF) in the wrist mature faster and work better for dialysis. It may be a good fit if you are an adult with a new fistula that hasn't been used yet.
Suzhou, JiangsuAges 18–75 - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06249880Recruiting
Studying how kids and young adults move without assistance
This study collects motion data from healthy children and young adults to create a baseline of normal movement. It may help doctors better understand typical development and identify movement problems in the future.
Puyallup, WashingtonAges 3–25 - NCT06250309Recruiting
Mediterranean diet vs. Western diet for fatigue in AIH
This study tests whether a Mediterranean diet can reduce fatigue in people with autoimmune hepatitis (AIH) compared to a typical Western diet. You will receive frozen meals for a week and track your energy levels.
Indianapolis, IndianaAges 18–80 - NCT06250465Recruiting
CLL registry for patients 18 and older
This registry collects information over time from people with CLL to better understand the disease and its treatment. It does not test any new drugs or procedures.
FeldkirchAges 18 years+ - NCT06250959RecruitingPhase 2
Comparing a new drug to standard chemo for B-ALL
This trial tests if a new drug, RDC-Blinatumomab, works better than the usual chemotherapy (hyperCVAD) for people with a type of leukemia called Ph-negative B-ALL. It is for newly diagnosed patients who haven't had other treatments yet.
Suzhou, JiangsuAges 15–65 - NCT06251076RecruitingPhase 4
Outpatient teclistamab for multiple myeloma: a safety study
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
Toronto, OntarioAges 18 years+ - NCT06251180RecruitingPhase 1
Rocbrutinib plus R-CHOP for newly diagnosed B-cell lymphoma
This trial tests a new targeted drug called rocbrutinib combined with the standard chemo-immunotherapy R-CHOP for people newly diagnosed with certain types of B-cell non-Hodgkin lymphoma. The goal is to see if adding rocbrutinib helps the standard treatment work better.
Guangzhou, GuangdongAges 18–70 - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06256146Recruiting
Treating food allergies with modified oral immunotherapy
This study tests a new approach to oral immunotherapy for food allergies, aiming to make it safer and more effective. It's for people who have had a clear allergic reaction to a food and have a positive allergy test.
Montreal, QuebecAges 2–40 - NCT06256614Recruiting
Washed stool transplant for type 1 diabetes
This trial tests if a washed microbiota transplant (a processed stool transplant from healthy donors) can help people with type 1 diabetes. It aims to see if this treatment can improve blood sugar control or reduce the need for insulin.
Nanjing, JiangsuAges 3–100 - NCT06258122Recruiting
Long-term health and aging in people with HIV
This study follows people with HIV and healthy volunteers over time to see how their health, immune system, and aging change. It aims to find ways to improve long-term care.
ParisAges 18 years+ - NCT06259669Recruiting
Studying eczema cream safety during pregnancy
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
Morrisville, North CarolinaAges 15–50 - NCT06261554Recruiting
Low-dose sesame oral immunotherapy for children
This study tests if a very low daily dose of sesame protein (given as a powder under the tongue) can help children with sesame allergy become less sensitive to sesame. The goal is to reduce the risk of severe allergic reactions from accidental exposure.
Warsaw, Masovian VoivodeshipAges 3–17 - NCT06263426Recruiting
Kidney transplant from donors with HIV: impact on rejection and long-term results
This study tests whether kidney transplants from donors with HIV are safe and effective for people with HIV who need a new kidney. It looks at long-term outcomes like rejection and survival.
Birmingham, AlabamaAges 18 years+ - NCT06263530Recruiting
Blood test for tumor DNA in Hodgkin lymphoma
This study looks at whether a blood test that checks for tiny pieces of tumor DNA (called ctDNA) can help predict how Hodgkin lymphoma will progress. It is for adults who have just been diagnosed with classical Hodgkin lymphoma.
Hradec KrálovéAges 18 years+ - NCT06263491RecruitingPhase 2
Pirtobrutinib and Rituximab for Low/Medium Risk MCL
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
Houston, TexasAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.